Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease
Susan H. Fox
Drugs (2013) Vol. 73, Iss. 13, pp. 1405-1415
Closed Access | Times Cited: 140

Showing 1-25 of 140 citing articles:

Motor symptoms in Parkinson’s disease: A unified framework
Ahmed A. Moustafa, V. Srinivasa Chakravarthy, Joseph R. Phillips, et al.
Neuroscience & Biobehavioral Reviews (2016) Vol. 68, pp. 727-740
Open Access | Times Cited: 340
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Delphine Charvin, Rossella Medori, Robert A. Hauser, et al.
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 11, pp. 804-822
Closed Access | Times Cited: 241
Parkinson’s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients
Nataša Kuštrimović, Cristoforo Comi, Luca Magistrelli, et al.
Journal of Neuroinflammation (2018) Vol. 15, Iss. 1
Open Access | Times Cited: 226
The impact of obesity on neurodegenerative diseases
Janaína Niero Mazon, Aline Haas de Mello, Gabriela K. Ferreira, et al.
Life Sciences (2017) Vol. 182, pp. 22-28
Closed Access | Times Cited: 153
Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications
Philippe De Deurwaerdère, Giuseppe Di Giovanni
Progress in Neurobiology (2016) Vol. 151, pp. 175-236
Closed Access | Times Cited: 151
Evidence of Inflammatory System Involvement in Parkinson’s Disease
Yinxia Chao, Siew Cheng Wong, Eng King Tan
BioMed Research International (2014) Vol. 2014, pp. 1-9
Open Access | Times Cited: 140
New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders
Giuseppe Di Giovanni, Philippe De Deurwaerdère
Pharmacology & Therapeutics (2015) Vol. 157, pp. 125-162
Closed Access | Times Cited: 103
History and Perspectives of A2AAdenosine Receptor Antagonists as Potential Therapeutic Agents
Delia Preti, Pier Giovanni Baraldi, Allan R. Moorman, et al.
Medicinal Research Reviews (2015) Vol. 35, Iss. 4, pp. 790-848
Open Access | Times Cited: 95
Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease
Muthuraman Muthuraman, Nabin Koirala, Dumitru Ciolac, et al.
Frontiers in Neurology (2018) Vol. 9
Open Access | Times Cited: 93
Antioxidant and Anti-inflammatory Effect of Nrf2 Inducer Dimethyl Fumarate in Neurodegenerative Diseases
Sarah Adriana Scuderi, Alessio Ardizzone, Irene Paterniti, et al.
Antioxidants (2020) Vol. 9, Iss. 7, pp. 630-630
Open Access | Times Cited: 88
Striatal cholinergic interneurons generate beta and gamma oscillations in the corticostriatal circuit and produce motor deficits
Krishnakanth Kondabolu, Erik A. Roberts, Mark E. Bucklin, et al.
Proceedings of the National Academy of Sciences (2016) Vol. 113, Iss. 22
Open Access | Times Cited: 86
Medical Management and Prevention of Motor Complications in Parkinson's Disease
Stephen Aradi, Robert A. Hauser
Neurotherapeutics (2020) Vol. 17, Iss. 4, pp. 1339-1365
Open Access | Times Cited: 80
Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence
Elisa Storelli, Niccolò Cassina, Emanuela Rasini, et al.
Frontiers in Neurology (2019) Vol. 10
Open Access | Times Cited: 77
Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease
Qi Mao, Wangzhi Qin, Ao Zhang, et al.
Acta Pharmacologica Sinica (2020) Vol. 41, Iss. 4, pp. 471-482
Open Access | Times Cited: 71
Pesticides and Parkinson’s disease: Current and future perspective
Md Shahidul Islam, Fazli Azim, Hedaeytullah Saju, et al.
Journal of Chemical Neuroanatomy (2021) Vol. 115, pp. 101966-101966
Closed Access | Times Cited: 64
Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases
Orkid Coskuner‐Weber, Ozan Mirzanli, Vladimir N. Uversky
Biophysical Reviews (2022) Vol. 14, Iss. 3, pp. 679-707
Open Access | Times Cited: 45
Tremor in Parkinson’s Disease: From Pathophysiology to Advanced Therapies
Ali Abusrair, Walaa Elsekaily, Saeed Bohlega
Tremor and Other Hyperkinetic Movements (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 45
Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited
Walter Pirker, Regina Katzenschlager, Mark Hallett, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 2, pp. 127-144
Open Access | Times Cited: 39
Trends and hotspots in non-motor symptoms of Parkinson’s disease: a 10-year bibliometric analysis
Xuefeng Li, Chunhai Chen, Ting Pan, et al.
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 11
Management of Parkinson׳s disease: Current and future pharmacotherapy
Ashish Kumar Kakkar, Neha Dahiya
European Journal of Pharmacology (2015) Vol. 750, pp. 74-81
Closed Access | Times Cited: 84
Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis
C. Cattaneo, Paolo Barone, Erminio Bonizzoni, et al.
Journal of Parkinson s Disease (2016) Vol. 7, Iss. 1, pp. 95-101
Open Access | Times Cited: 81
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis
C. Cattaneo, Roberto La Ferla, Erminio Bonizzoni, et al.
Journal of Parkinson s Disease (2015) Vol. 5, Iss. 3, pp. 475-481
Open Access | Times Cited: 74
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study
Nobutaka Hattori, Yoshio Tsuboi, Akihiko Yamamoto, et al.
Parkinsonism & Related Disorders (2020) Vol. 75, pp. 17-23
Open Access | Times Cited: 67
Safinamide: First Global Approval
Emma D. Deeks
Drugs (2015) Vol. 75, Iss. 6, pp. 705-711
Closed Access | Times Cited: 66
Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson’s Disease
Nataša Kuštrimović, Franca Marino, Marco Cosentino
Current Medicinal Chemistry (2018) Vol. 26, Iss. 20, pp. 3719-3753
Closed Access | Times Cited: 63
Page 1 - Next Page

Scroll to top